The Sanford guide to antimicrobial therapy 2020 (Record no. 38157)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04437nam a22002417a 4500 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| ISBN | 9781944272135 |
| 050 ## - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | MED RM265 |
| Item number | .S26 |
| 245 ## - TITLE STATEMENT | |
| Title | The Sanford guide to antimicrobial therapy 2020 |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 50th ed. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication | Sperryville, Va. |
| Name of publisher | Antimicrobial Therapy |
| Year of publication | 2020 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Number of Pages | 304 p. |
| 500 ## - GENERAL NOTE | |
| General note | Includes index<br/>Chiefly tables |
| 505 ## - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Abbreviations<br/>Table 1. Clinical approaches to initial choice of antimicrobial therapy<br/>Table 2. Recommended antimicrobial agents against selected bacteria<br/>Table 3. Suggested duration of antibiotic therapy for selected clinical syndromes in immunocompetent patients<br/>Table 4A. Antibacterial activity spectra<br/>Table 4B. Antifungal activity spectra<br/>Table 4C. Antiviral activity spectra<br/>Table 5A. Treatment options for systemic infection due to multi-drug resistant gram-positive bacteria<br/>Table 5B. Treatment options for systemic infection due to culture-identified multi-drug resistant gram-negative bacilli<br/>Table 6. Suggested management of suspected or culture-positive methicillin-resistant S. aureus infections<br/>Table 7. Antibiotic hypersensitivity reactions & drug desensitization methods<br/>Table 8. Pregnancy risk and safety in lactation<br/>Table 9A. Selected pharmacologic features of antimicrobial agents<br/>Table 9B. Pharmacodynamics of antibacterials<br/>Table 9C. Enzyme- and transporter- mediated interactions of antimicrobials<br/>Table 10A. Antibiotic dosage and side-effects<br/>Table 10B. Antimicrobial agents associated with photosensitivity<br/>Table 10C. Aminoglycoside once daily and multiple daily dosing regimens<br/>Table 10D. Prolonged or continuous infusion dosing of selected antibodies<br/>Table 10E. Inhalation antibiotics<br/>Table 11A. Treatment of fungal infections<br/>Table 11B. Antifungal drugs : Dosage, adverse effects, comments<br/>Table 12A. Treatment of mycobacterial infections<br/>Table 12B. Dosage and adverse effects of antimycobacterial drugs<br/>Table 13A. Treatment of parasitic infections<br/>Table 13B. Dosage and selected adverse effects of antiparasitic drugs<br/>Table 13C. Parasites that cause Eosinophilia (Eosinophilia in travelers)<br/>Table 13D. Sources for hard-to-find antiparasitic drugs<br/>Table 14A. Antiviral therapy<br/>Table 14B. Antiviral drugs (Non-HIV)<br/>Table 14C. Antiretroviral Therapy (ART) in treatment-naïve adults (HIV/AIDS)<br/>Table 14D. Antiretroviral drugs and adverse effects<br/>Table 14E. Hepatitis A & HBV treatment<br/>Table 14F. HCV treatment regimens and response<br/>Table 15A. Antimicrobial prophylaxis for selected bacterial infections<br/>Table 15B. Antibiotic prophylaxis to prevent surgical infections in adults<br/>Table 15C. Antimicrobial prophylaxis for the prevention of bacterial endocarditis in patients with underlying cardiac conditions<br/>Table 15D. Management of exposure to HIV-1 and Hepatitis B and C<br/>Table 15E. Prevention of selected opportunistic infections in Human Hematopoietic Cell Transplantation (HCT) or Solid Organ Transplantation (SOT) in adults with normal renal function<br/>Table 16. Pediatric dosing (Age >28 days)<br/>Table 17A. Dosage of antimicrobial drugs in adult patients with renal impairment<br/>Table 17B. No dosage adjustment wit renal insufficiency by category<br/>Table 17C. Antimicrobial dosing in obesity<br/>Table 17D. No dosing adjustments required in obesity<br/>Table 18. Antimicrobials and hepatic disease : Dosage adjustment<br/>Table 19. Treatment of CAPD peritonitis in adults<br/>Table 20A. Anti-tetanus prophylaxis, wound classification, immunization<br/>Table 20B. Rabies postexposure prophylaxis<br/>Table 21. Selected directory of resources<br/>Table 22A. Anti-infective drug-drug interactions<br/>Table 22B. Drug-drug interactions between Non-nucleoside Reverse Transcriptase inhibitors (NNRTIS) and protease inhibitors<br/>Table 23. List of generic and trade names<br/>Index |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | "This 50th edition of the Sanford Guide to Antimicrobial Therapy continues to provide accessible, concise, evidence-based guidance for appropriate treatment of infectious diseases. As drug resistance continues to narrow treatment options, antimicrobial stewardship only increases in importance."--taken from back of front cover<br/> |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical Term | Anti-Bacterial Agents therapeutic use |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gilbert, David N. (Editor) |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Chambers, Henry F. (Editor) |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Eliopoulos, Georges M. (Editor) |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Saag, Michael S. (Editor) |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pavia, Andrew P. (Editor) |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | Books |
| Withdrawn status | Lost status | Not for loan | Home library | Current library | Shelving location | Date entered | Source of acquisition | Cost, normal purchase price | Full call number | Bar code | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Directorate of Library Services | Directorate of Library Services | General Collection | 01/24/2025 | Donation | 22618.84 | MED RM265. S26 | 000000234570 | Books |